Imcyse, a Liège, Belgium-based developer of active specific immunotherapies for the treatment and prevention of severe chronic diseases, raised €35M ($39.5M) in Series B financing round and through other channels.
The round of €28M ($31.6M) in equity was led by LSP together with Belgian investors including Epimède, the Société Régionale d’Investissement de Wallonie (SRIW), and the Société Fédérale de Participations et d’Investissement (SFPI). Existing shareholders (Biogenosis, Noshaq, KU Leuven) also participated in the round.
Further to this, Imcyse also received a grant worth €4.6M ($5.2M) from the Walloon region (DGO6) and a bank loan of €2M ($2.3M) from Belfius.
These proceeds will be used to advance phase 2 clinical development of Imcyse’s Imotopes™ technology in type 1 diabetes, to initiate clinical trials in multiple sclerosis and other auto-immune diseases and to expand the technology to further indications.
Led by Pierre Vandepapelière, CEO and CMO, Imcyse develops active targeted immunotherapies to treat and prevent severe chronic diseases caused by disruptions of the immune system. The company’s active immunotherapy technology platform allows it to destroy locally the immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specific modified peptides, allowing for the generation of a new type of T-cell, called cytolytic CD4.
Founded in 2010, Imcyse is a spin-off from the KU Leuven university, Belgium.